OBJECTIVES: This study sought to characterize the prevalence of metabolic syndrome (MetS), its 5 components, and their pharmacological treatment in U.S. adults by sex and race/ethnicity over time. BACKGROUND: MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease, and type 2 diabetes mellitus. METHODS: Prevalence estimates were estimated in adults (≥ 20 years of age) from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010 (in 2-year survey waves). The biological thresholds, defined by the 2009 Joint Scientific Statement, were: 1) waist circumference ≥ 102 cm (males adults) and ≥ 88 cm (female adults); 2) fasting plasma glucose ≥ 100 mg/dl; 3) blood pressure of ≥ 130/85 mm Hg; 4) triglycerides ≥ 150 mg/dl; and 5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (male adults) and <50 mg/dl (female adults). Prescription drug use was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic medications. RESULTS: From 1999 and 2000 to 2009 and 2010, the age-adjusted prevalence of MetS (based on biologic thresholds) decreased from 25.5% (95% confidence interval [CI]: 22.5% to 28.6%) to 22.9% (95% CI: 20.3% to 25.5%). During this period, hypertriglyceridemia prevalence decreased (33.5% to 24.3%), as did elevated blood pressure (32.3% to 24.0%). The prevalence of hyperglycemia increased (12.9% to 19.9%), as did elevated waist circumference (45.4% to 56.1%). These trends varied considerably by sex and race/ethnicity. Decreases in elevated blood pressure, suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have corresponded with increases in anti-hypertensive and lipid-modifying drugs, respectively. CONCLUSIONS: The increasing prevalence of abdominal obesity, particularly among female adults, highlights the urgency of addressing abdominal obesity as a healthcare priority. The use of therapies for MetS components aligns with favorable trends in their prevalence.
OBJECTIVES: This study sought to characterize the prevalence of metabolic syndrome (MetS), its 5 components, and their pharmacological treatment in U.S. adults by sex and race/ethnicity over time. BACKGROUND: MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease, and type 2 diabetes mellitus. METHODS: Prevalence estimates were estimated in adults (≥ 20 years of age) from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010 (in 2-year survey waves). The biological thresholds, defined by the 2009 Joint Scientific Statement, were: 1) waist circumference ≥ 102 cm (males adults) and ≥ 88 cm (female adults); 2) fasting plasma glucose ≥ 100 mg/dl; 3) blood pressure of ≥ 130/85 mm Hg; 4) triglycerides ≥ 150 mg/dl; and 5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (male adults) and <50 mg/dl (female adults). Prescription drug use was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic medications. RESULTS: From 1999 and 2000 to 2009 and 2010, the age-adjusted prevalence of MetS (based on biologic thresholds) decreased from 25.5% (95% confidence interval [CI]: 22.5% to 28.6%) to 22.9% (95% CI: 20.3% to 25.5%). During this period, hypertriglyceridemia prevalence decreased (33.5% to 24.3%), as did elevated blood pressure (32.3% to 24.0%). The prevalence of hyperglycemia increased (12.9% to 19.9%), as did elevated waist circumference (45.4% to 56.1%). These trends varied considerably by sex and race/ethnicity. Decreases in elevated blood pressure, suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have corresponded with increases in anti-hypertensive and lipid-modifying drugs, respectively. CONCLUSIONS: The increasing prevalence of abdominal obesity, particularly among female adults, highlights the urgency of addressing abdominal obesity as a healthcare priority. The use of therapies for MetS components aligns with favorable trends in their prevalence.
Authors: Margaret D Carroll; David A Lacher; Paul D Sorlie; James I Cleeman; David J Gordon; Michael Wolz; Scott M Grundy; Clifford L Johnson Journal: JAMA Date: 2005-10-12 Impact factor: 56.272
Authors: Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: Paula F Rosenbaum; Ruth S Weinstock; Allen E Silverstone; Andreas Sjödin; Marian Pavuk Journal: Environ Int Date: 2017-08-02 Impact factor: 9.621
Authors: Lisa Kobos; Saeed Alqahtani; Li Xia; Vincent Coltellino; Riley Kishman; Daniel McIlrath; Carlos Perez-Torres; Jonathan Shannahan Journal: J Toxicol Environ Health A Date: 2020-04-12
Authors: Jennifer W Bea; Peter W Jurutka; Elizabeth A Hibler; Peter Lance; Maria E Martínez; Denise J Roe; Christine L Sardo Molmenti; Patricia A Thompson; Elizabeth T Jacobs Journal: Metabolism Date: 2014-11-29 Impact factor: 8.694
Authors: Bradley M Appelhans; Eisuke Segawa; Imke Janssen; Lisa M Nackers; Rasa Kazlauskaite; Ana Baylin; John W Burns; Lynda H Powell; Howard M Kravitz Journal: Prev Med Date: 2014-12-06 Impact factor: 4.018
Authors: Robert E Heinl; Devinder S Dhindsa; Elliot N Mahlof; William M Schultz; Johnathan C Ricketts; Tina Varghese; Amirhossein Esmaeeli; Marc P Allard-Ratick; Anthony J Millard; Heval M Kelli; Pratik B Sandesara; Danny J Eapen; Laurence Sperling Journal: Can J Cardiol Date: 2016-07-22 Impact factor: 5.223